BIOCONJUGATE INSIGHTS

In this issue, we examine how tumor heterogeneity and acquired resistance are shaping ADC design, from dual-targeting and conditional activation to site-specific conjugation and tumor-selective release. Explore why matching the payload class to the biology of resistance matters as much as choosing the target, and chart a bioconjugate landscape that is still concentrated on topoisomerase-1 inhibitor payloads but is increasingly working to move beyond them.

“The therapy itself … exerts a selective pressure that can drive the growth of the cell populations it cannot effectively target.” – Zoë Jukes, Toni Wyllie, and Adam Lodge, Iksuda Therapeutics

“If resistance develops to a Topo inhibitor, you change the payload mechanism.” – Valerie Vanhooren, Co-Founder and CEO, Ona Therapeutics

In this issue, we examine how linker chemistry has become a central lever for defining the therapeutic window. Explore why the whole ADC molecule has to be designed as one, and chart a bioconjugate landscape where developers are increasingly differentiating on construct rather than target.

"Parts of an ADC cannot be designed in isolation; the whole molecule has to be considered."
– Michael Lukesch, Founder and CEO, Valanx

"The linker cannot be optimized independently of the payload or the antibody, and it cannot be divorced from the target biology."
– Brian A Mendelsohn, Independent Industry Consultant and ADC Veteran

FEATURING

Issue Spotlight: Manufacturing strategies to move the bioconjugate field forward

FEATURING

Issue Spotlight: Building the ideal bioconjugate scaffold through antibody discovery and engineering

FEATURING

Issue Spotlights: Manufacturing strategies to move the bioconjugate field forward | Tackling site-specificity in ADCs

FEATURING

Issue Spotlight: Linker design and payload innovation

FEATURING

Issue Spotlight: From bench to bedside: translating ADCs into the clinic